Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.